secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001404644-24-000103
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene Q3 net loss $20.2M; positive NGN-401 data; $200M private placement
----------------------------------------------------------------------------

- Q3 net loss $20.2M vs $14.6M YoY; cash & investments $139M as of Sep 30, 2024.
- First 4 NGN-401 participants at 1E15 vg showed consistent improvements; 28-52% RSBQ improvement.
- SAE at 3E15 vg dose; FDA allows continued enrollment at 1E15 vg; enrollment paused for protocol revision.
- NGN-101 CLN5 Batten program discontinued after RMAT application denied; options being evaluated.
- Closed ~$200M private placement extending cash runway into second half of 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000103/0001404644-24-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000103/ngne-20241118.htm
  HTML page:      https://secwatch.observer/filing/0001404644-24-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer